Oslo, Norway, April 17, 2026 – Nykode Therapeutics ASA (OSE: NYKD), a clinical-stage biopharmaceutical company dedicated to the discovery and development of novel immunotherapies, today announced the publication of the Annual Report for 2025.
The Board of Directors of Nykode Therapeutics ASA has approved the annual accounts for 2025. The financial statements and annual report for the financial year 2025 are attached in European Single Electronic Format (ESEF) and as a PDF file.
The documents are also available in the investors section of the Company’s website: https://nykode.com/investors/financial-reports/
Annual Report 2025 ESEF
